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Abstract
Background: Mefloquine has historically been considered safe and well-tolerated for long-term
malaria chemoprophylaxis, but prescribing it requires careful attention in order to rule out
contraindications to its use. Contraindications include a history of certain neurological conditions
that might increase the risk of seizure and other adverse events. The precise pathophysiological
mechanism by which mefloquine might predispose those with such a history to seizure remains
unclear.
Presentation of the hypothesis: Studies have demonstrated that mefloquine at doses
consistent with chemoprophylaxis accumulates at high levels in brain tissue, which results in altered
neuronal calcium homeostasis, altered gap-junction functioning, and contributes to neuronal cell
death. This paper reviews the scientific evidence associating mefloquine with alterations in neuronal
function, and it suggests the novel hypothesis that among those with the prevalent EPM1 mutation,
inherited and mefloquine-induced impairments in neuronal physiologic safeguards might increase
risk of GABAergic seizure during mefloquine chemoprophylaxis.
Testing and implications of the hypothesis: Consistent with case reports of tonic-clonic
seizures occurring during mefloquine chemoprophylaxis among those with family histories of
epilepsy, it is proposed here that a new contraindication to mefloquine use be recognized for
people with EPM1 mutation and for those with a personal history of myoclonus or ataxia, or a
family history of degenerative neurologic disorder consistent with EPM1. Recommendations and
directions for future research are presented.
Background
Mefloquine (Lariam®) is a commonly prescribed anti-
malarial. Although historically the long-term use of
mefloquine for malaria chemoprophylaxis has been con-
sidered safe and well-tolerated [1,2], careful prescribing is
needed to minimize the potential for severe neurological
adverse events, including myoclonus and seizure, for
which individuals with certain neurological histories
appear to be at highest risk [3]. In particular, case-report
[4], case-series [5], and retrospective cohort [6,7] studies
define a well-characterized pattern of increased suscepti-
bility to seizure and other movement disorders including
nystagmus and ataxia [4] with use of mefloquine among
those with a personal [4-6] or family history [7] of such
conditions. Additional case-reports describe, in the
absence of personal or family history, the occurrence of
multifocal myoclonus [8], convulsions, and seizures fol-
lowing both therapeutic [9] and prophylactic doses [10-
12] when mefloquine is co-administered with other med-
ications such as fluroquinolones [13], or occasionally
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when mefloquine administration is preceded by non-spe-
cific neurologic prodrome [14].
The U.S. package insert cautions that mefloquine "should
not be prescribed for prophylaxis in patients with active depres-
sion, a recent history of depression, generalized anxiety disor-
der, psychosis, or schizophrenia or other major psychiatric
disorders, or with a history of convulsions" [15]. The preva-
lence of these contraindications is approximately 9–10%
in both military [16] and civilian [17] populations that
present for malaria chemoprophylaxis, which underscores
that clinicians must exercise significant care prior to pre-
scribing and dispensing mefloquine.
A growing body of recent evidence from in vitro and in vivo
studies in animal models characterize the direct neuro-
toxic effects of mefloquine [18-22], the ability of meflo-
quine to disrupt normal neuronal calcium homeostasis
[21,23,24], as well as cellular calcium homeostasis [25],
and mefloquine's inhibition of normal gap-junction func-
tion [26-28]. Many of these results are readily demon-
strated at concentrations consistent with
chemoprophylaxis [21,22,26]. Despite these advances in
understanding, the precise pathophysiological mecha-
nism remains unclear by which mefloquine predisposes
to seizure people with a personal or family history of cer-
tain neurological conditions [3].
A satisfying explanation for the pathogenic mechanism of
mefloquine-induced epileptogenesis would integrate cur-
rent knowledge of mefloquine neurotoxicity with an
understanding of the pathogenic mechanism underlying
clinical conditions that mirror the clinical presentation of
mefloquine-associated seizure. Furthermore, such an
explanation would elucidate why these reactions occur in
specific populations. This opinion paper reviews recent
research and presents a novel hypothesis, consistent with
these axioms, that offers an explanation for why meflo-
quine may predispose to seizure certain individuals with
EPM1 genotype.
Presentation of the hypothesis
Mefloquine accumulates at high concentrations in brain 
tissue
Mefloquine is a highly lipotropic drug which readily
crosses the blood-brain barrier [29,30] and whose efflux
from neuronal tissues is mediated by the efflux pump P-
glycoprotein (P-gp) [29,31]. In rat models a neuronal
accumulation of enantiomeric mefloquine supports a
stereoselective active neuronal efflux, and in in vivo mouse
models, the neuronal concentration of quinine is raised in
the presence of mefloquine [32]. Mefloquine is, therefore,
both a substrate and an inhibitor of P-gp [31,33].
Under conditions of long-term chemoprophylaxis, meflo-
quine levels in plasma have been reported between 1.5
and 3.3 μM [34], but relatively few post-mortem studies
have defined concentrations in brain tissue under condi-
tions of chemoprophylaxis. One post-mortem case-series
identified mefloquine in brain tissue at concentrations
between 8.7 and 14 mg/kg [35], corresponding to signifi-
cantly higher molar concentrations of between 21 and 34
μM. Another post-mortem study demonstrated ratios of
brain white matter to serum mefloquine of 22.9:1 and
55.5:1 for (-) and (+) enantiomeric mefloquine, respec-
tively [30]. This same study found grey matter concentra-
tions were approximately 69% of that found in white
matter [30]. Based on these data it is reasonable to con-
clude that mefloquine typically accumulates in brain tis-
sue at concentrations approximately 10–30 times higher
than found in serum [21].
The MDR1 gene codes for P-gp. Research postulates that
polymorphisms in the MDR1 gene that result in a reduced
expression of P-gp will result in lower mefloquine efflux
from the brain and lead to higher brain tissue concentra-
tions [33] than in individuals lacking these polymor-
phisms. Studies have demonstrated that the
neuropsychiatric effects of mefloquine, as identified by
earlier cohort studies [36], are more common among
those with MDR1 polymorphisms [33]. It is therefore
plausible that common MDR1 polymorphisms, by signif-
icantly raising neuronal levels of mefloquine, might medi-
ate the propensity towards dose-dependent adverse
events.
Mefloquine interferes with normal gap junction 
functioning
Mefloquine exhibits a potent dose-dependent ability to
interfere with the functioning of gap junctions, which are
inter-neuronal channels created by distinct oligomeric
proteins called connexins [37]. A variety of connexin (Cx)
proteins have been identified and characterized, identi-
fied by their molecular weight [37]. Of these, Cx36 and
Cx43 are widely distributed in neuronal tissue and show
sensitivity to mefloquine.
Gap junctions formed by Cx36 predominate in neurons
[38] in rat models, and play a critical role in the direct
transport of ions between adjacent neurons, a process
known as neuronal coupling [39]. Cx36 is found at high
concentrations within the inhibitory GABAergic interneu-
rons of the cortical striatum [39]. In mouse and rat mod-
els, Cx36 is also found throughout the ventral tegmental
area [40], the neocortex [26], thalamic reticular nucleus
[26], inferior olive [38,41], and possibly hippocampus
[26].Malaria Journal 2009, 8:188 http://www.malariajournal.com/content/8/1/188
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Lack of functioning Cx36 has been implicated in epilep-
togenesis [42], although the underlying mechanism is not
clear. In mice lacking Cx36, deficits are found in synchro-
nous firing within cortical, thalamic, and brainstem cir-
cuits [26]. Gene-transfer research demonstrates
inactivation of Cx36 in mature rat models results in meas-
urable degradation in fine temporal coordination of mus-
cle firing [41]. Mefloquine blockade of Cx36 also
suppresses essential tremor when induced in mouse mod-
els [28]. At high concentrations, mefloquine also
decreases the amplitude of Cx36-mediated cortical
spreading depression in rat models in vitro [27].
Significant physiological effects due to mefloquine are
noted at concentrations consistent with chemoprophy-
laxis. At concentrations of 25 μM, mefloquine inhibition
of Cx36 in in vivo mouse models is associated with a
decrease in GABAergic spontaneous synaptic currents to
motor neurons [39]. In in vitro studies, mefloquine at con-
centrations as low as 10 μM significantly reduced cortical
coupling, and at 25 μM mefloquine caused increases in
spontaneous chemical synaptic activity [26]. In in invo
studies in rats, mefloquine at concentrations of 25 μM
antagonized the stimulatory action of modafinil, likely
through decreased gap junction-mediated electrical cou-
pling [43].
The predominant connexin expressed in neuronal glial
tissue is Cx43, which is thought to permit the transfer of
small molecular weight molecules critical to maintenance
of cellular homeostasis [37]. Functioning gap junctions in
the astrocyte network serves to dilute substances cleared
from the extracellular environment, including free cal-
cium [37]. At levels of 30 μM, mefloquine strongly inhib-
its Cx43 [26].
Mefloquine disrupts intracellular calcium homeostasis
Mefloquine in vitro also strongly interferes with neuronal
calcium homeostasis, likely through inhibitory action on
the endoplasmic reticulum (ER) calcium ATPase, leading
to the intracellular release of the ER calcium stores [21].
These effects have been consistently noted in rat neurons
in vitro at concentrations of between 10–30 μM [21,22]. In
a dog model, mefloquine inhibits inositol-1,4,5-phos-
phate (IP3)-mediated calcium release from neuronal
microsome stores, although at slightly higher molar con-
centrations [24], suggesting a role for mefloquine in IP3-
receptor (IP3-R)-mediated signal transduction processes.
Mefloquine produces dose-dependent neuronal toxicity
In rat model experiments, mefloquine produces perma-
nent and dose-dependent brain stem lesions in the
nucleus gracilis, nuclear cuneatus, and solitary tract [20].
These lesions were accompanied by dose-dependent
impairments in motor performance consistent with loss
of vestibular or nucleus gracilis-dependent proprioceptive
function. Inhibition of cytoplasmic calcium homeostasis
might trigger a shutdown of protein synthesis [23], result-
ing in an induction of proapoptotic mediators and con-
tributing to the drug's neurotoxic effects [21]. Such lesions
were moderately demonstrated at doses of 187 mg/kg,
corresponding with rat plasma concentrations of 2.1 μg/
mL [20] or approximately 5.6 μM plasma concentration.
Significance of EPM1 mutation
Unverricht-Lundborg Disease (ULD) is an inheritable,
autosomal recessive, degenerative form of epilepsy char-
acterized as progressive and myoclonic, type 1 (EPM1)
[44]. ULD is generally diagnosed prior to age 18, and in
half of cases the first presentation is tonic-clonic seizure
[44]. EPM1 homozygosity is characterized by the early
onset of progressive ataxia, incoordination, intentional
tremor and dysarthria.
Genetic studies have revealed that EPM1 is associated with
loss of function in the cystatin B gene (CSTB) in over 90%
of cases [45] due to a dodecamer repeat expansion in the
CSTB promoter [45] that results in significant downregu-
lation of mRNA expression. CSTB protects against the pro-
teolytic activity of cathepsin cystein proteases, particularly
capthepsin B [45], and the main function of cytosolic
CSTB in normal physiology is thought to be protection
from lysosomal protease leakage [46]. However, in CSTB
knock-out mice, ataxia, myoclonic seizures, rapid cerebel-
lar degeneration and apoptosis are noted [47] and are
associated with significant increases in transcription of
cathepsin S and markers of glial activation [48], them-
selves consistent with reactive changes suggestive of wide-
spread cortical and subcortical grey matter damage [49].
CSTB knock-out mice also demonstrate increased suscep-
tibility  in vivo to severe seizure, including generalized
tonic-clonic seizures, and in vitro exhibit neuronal hyper-
excitability characterized by decreased seizure threshold
[50].
Additionally, mouse studies demonstrate that EPM1 het-
erozygosity results in lower cystatin B expression than
wild-type mice and is associated also with near-universal
mild neurogeneration and neuronal atrophy [51]. In
some cases heterozygosity also might be associated with
mild signs and symptoms of ULD, including ataxia, motor
incoordination and myoclonus [51].
These results suggests that CSTB deficiency creates impair-
ments in the normal spectrum of neuronal physiologic
safeguards, which predisposes EPM1 heterozygotes to
neuronal hyperexcitability and hastens neuronal cell
death with seizure [50].Malaria Journal 2009, 8:188 http://www.malariajournal.com/content/8/1/188
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Epileptogenic potential of mefloquine in EPM1 
heterozygotes
Despite the absence in the literature of such events being
reported, and based solely on biologic plausibility, the
previous findings support the novel hypothesis that EPM1
heterozygosity might substantially increase the risk of sei-
zure among subjects exposed to mefloquine, particularly
in the presence of an MDR1 polymorphism or other con-
dition, including the co-administration of a P-gp inhibi-
tory drug that raises brain concentrations of mefloquine.
Among people with EPM1 mutation and exposed to
mefloquine at an as-yet undetermined threshold grey-
matter concentration, inherited predisposition to and
reductions in physiologic protection from apoptosis are
postulated to be exacerbated by a mefloquine-induced
dysfunction among a spectrum of ordinarily complemen-
tary neuronal physiologic safeguards that become altered
in mefloquine's presence. These altered physiologic safe-
guards include a loss of normal neuronal calcium home-
ostasis via mefloquine-induced release of ER calcium
stores, altered glial cell function via mefloquine-induced
Cx43-mediated gap junction dysfunction; and decreased
GABAergic cortical inhibition and coupling and increased
motor-neuron synaptic activity via mefloquine-induced
Cx36-mediated gap junction dysfunction.
Although the precise role of altered astrocyte gap function
in mediating apoptosis is not yet clear [52], it might be
that in the presence of mefloquine-induced Cx43 dysfunc-
tion, increased neuronal cellular calcium resulting from
inhibition of ER calcium ATPase is mediated less effec-
tively by the astrocyte network, which then more readily
induces neuronal proapoptotic mechanisms themselves
promoted by mefloquine.
Simultaneously, it might be that mefloquine-induced
Cx36 dysfunction results in decreased inhibitory GABAer-
gic input and increased spontaneous synaptic activity.
Supporting this postulate are results from in vivo mouse
models, which demonstrate that high-dose mefloquine
induces seizure, and that this effect is blocked by potent
GABA agonists [53].
Given the simultaneous loss of multiple neuroprotective
safeguards associated with mefloquine administration, it
is, therefore, plausible that the first manifestation of sei-
zure in EPM1 heterozygotes might occur with mefloquine
prophylaxis.
Implications and testing of the hypothesis
Consistent with case reports of tonic-clonic seizures
occurring during mefloquine chemoprophylaxis among
those with family histories of epilepsy [7], out of an abun-
dance of caution and based on biological plausibility,
consideration should be given to a contraindication to
mefloquine use among those with EPM1 mutation; or
absent formal genetic diagnosis, among those with a per-
sonal or family history of seizure, myoclonus, ataxia, or
degenerative neurologic disorder consistent with EPM1.
Such a contraindication would expand upon and clarify
existing U.S. package-insert guidance that limits existing
neurologic contraindications to a personal "history of con-
vulsions."
The prevalence of EPM1 homozygosity is as high as four
per 100,000 in some western populations [44], which
suggests that the genotypic frequency of EPM1 heterozy-
gosity under Hardy-Weinberg equilibrium could exceed
one percent. Such underlying prevalence might be consist-
ent with the incidence of observed neurologic adverse
events with mefloquine prophylaxis, particularly when
coupled with an as-yet-unclear population prevalence of
either MDR1 polymorphisms, co-administration of med-
ication which may further inhibit P-gp function, or other
conditions such as liver dysfunction which may decrease
metabolism and, therefore, lead to increases in neuronal
mefloquine concentrations.
Post-marketing studies, including genetic studies testing
for EPM1 mutation among people who have suffered
severe seizures following the prophylactic or therapeutic
use of mefloquine should be conducted to further eluci-
date this alleged risk. Additionally, post-mortem studies
should be conducted also to better characterize the corre-
lations between brain concentrations of mefloquine,
prevalent genetic mutations including EPM1 and MDR-1,
co-morbid liver dysfunction including alcohol- and drug-
induced impairments, and the extent of neuronal apopto-
sis that occur under conditions of chemoprophylaxis.
Although obtaining access to large numbers of post-mor-
tem specimens exposed to mefloquine chemoprophylaxis
has proven challenging historically, ongoing U.S. military
efforts in malarious areas, including Afghanistan, Africa,
Asia, and South America, present an unfortunate but
meaningful opportunity to improve understanding in this
area. Because mefloquine has until recently served as pri-
mary chemoprophylaxis for U.S. service members
deployed to some of these areas, [16], and may still be
used by a significant proportion of the U.S. military pop-
ulation [54], the direct measurement of brain mefloquine
concentrations [35] and the extent of neuronal apoptosis
during U.S. military-directed post-mortem examination,
would assist greatly in improving understanding of these
and other recently postulated mechanisms of mefloquine
neurotoxicity [55].Malaria Journal 2009, 8:188 http://www.malariajournal.com/content/8/1/188
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